STOCK TITAN
  1. Home
  2. News
  3. KRYS

Krystal Biotech Inc - KRYS STOCK NEWS

Welcome to our dedicated news page for Krystal Biotech (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Krystal Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Krystal Biotech's position in the market.

News
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) presents new preclinical data on intratumoral delivery of IL-12 and IL-2, showing enhanced local and systemic effector T-cell responses in a cold tumor preclinical model at AACR 2024 Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
-
News
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) will participate in the TD Cowen 44th Annual Health Care Conference in Boston. Chairman and CEO Krish S. Krishnan will host a fireside chat and investor meetings. A webcast of the presentation will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
conferences
-
News
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Krystal Biotech reports strong financial results with $42.1M in net product revenue in 4Q and $50.7M for the year, FDA alignment for B-VEC eyedrop formulation, and initiation of Phase 1 KB408 trial for AATD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.02%
Tags
earnings
News
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) will release its Q4 and full year 2023 financial results on February 26, 2024, followed by a webcast for financial updates. An investor webcast will also be held on the same day at 8:30 am ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
conferences earnings
-
News
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
Rhea-AI Summary
Krystal Biotech, Inc. receives FDA Fast Track Designation for inhaled KB707 in the treatment of solid tumors with pulmonary metastases. Phase 1 clinical trial (KYANITE-1) expected to start in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
clinical trial
-
News
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
Rhea-AI Summary
Krystal Biotech, Inc. announces positive clinical data on the compassionate use of B-VEC, an eyedrop treatment for patients with dystrophic epidermolysis bullosa (DEB) with ocular complications. The NEJM publication showed significant visual acuity improvement and full corneal healing in a patient treated with B-VEC, indicating potential benefits for DEB patients with ocular lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
News
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) will participate in the Guggenheim 6th Annual Biotechnology Conference in New York on February 7-8. The Chairman and CEO will host investor meetings and a webcast of the presentation will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
-
News
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
Rhea-AI Summary
Krystal Biotech, Inc. (NASDAQ: KRYS) announced that the U.S. Centers for Medicare & Medicaid Services has assigned a permanent and product-specific J-code for VYJUVEK, the first FDA-approved treatment for dystrophic epidermolysis bullosa (DEB). The J-code (J3401) became effective on January 1, 2024, ensuring efficient and accurate reimbursement for the treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
News
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
Rhea-AI Summary
Krystal Biotech, Inc. (NASDAQ: KRYS) receives Orphan Drug Designation (ODD) from Japan Ministry of Health, Labour and Welfare (MHLW) for beremagene geperpavec-svdt (B-VEC or VYJUVEK) to treat dystrophic epidermolysis bullosa (DEB)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
clinical trial
News
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for VYJUVEK (beremagene geperpavec-svdt, also known as B-VEC) to treat dystrophic epidermolysis bullosa (DEB) in the European Union. The CHMP opinion is expected in the second half of 2024. VYJUVEK has received Orphan Drug Designation, PRIME designation, and a positive opinion from the EMA Pediatric Committee, potentially leading to additional marketing exclusivity in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
Stock KRYS logo
Krystal Biotech Inc

Nasdaq:KRYS

KRYS Rankings

#1216 Ranked by Market Cap
#396 Ranked by Stock Gains
N/A Ranked by Dividends

KRYS Stock Data

4.95B
20.55M
12.91%
89.03%
7.62%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Pittsburgh

About KRYS

krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)